ANEB Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

$2.65
As of 12/02/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/07/2021
Outstanding shares:  25,633,217
Average volume:  7,952
Market cap:   $64,083,043
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.30
PS ratio:   0.00
Return on equity:   -195.86%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy